Diarylquinolines Are Bactericidal for Dormant Mycobacteria as a Result of Disturbed ATP Homeostasis
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
An estimated one-third of the world population is latently infected with Mycobacterium tuberculosis. These nonreplicating, dormant bacilli are tolerant to conventional anti-tuberculosis drugs, such as isoniazid. We recently identified diarylquinoline R207910 (also called TMC207) as an inhibitor of ATP synthase with a remarkable activity against replicating mycobacteria. In the present study, we show that R207910 kills dormant bacilli as effectively as aerobically grown bacilli with the same target specificity. Despite a transcriptional down-regulation of the ATP synthase operon and significantly lower cellular ATP levels, we show that dormant mycobacteria do possess residual ATP synthase enzymatic activity. This activity is blocked by nanomolar concentrations of R207910, thereby further reducing ATP levels and causing a pronounced bactericidal effect. We conclude that this residual ATP synthase activity is indispensable for the survival of dormant mycobacteria, making it a promising drug target to tackle dormant infections. The unique dual bactericidal activity of diarylquinolines on dormant as well as replicating bacterial subpopulations distinguishes them entirely from the current anti-tuberculosis drugs and underlines the potential of R207910 to shorten tuberculosis treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



![FIGURE 4 ATP synthase is functional in dormant M. smegmatis . A , ATP synthesis activity in inverted membrane vesicles (50 𝛍 g/ml) from dormant M. smegmatis cultured for 10 days under Wayne O 2 depletion conditions. Positive control was membrane vesicles with buffer containing ADP, P i , and NADH, whereas negative control excluded NADH and Pi from the assay buffer. B , effect of R207910 on membrane potential in dormant M. smegmatis cultured for 10 days under Wayne O 2 depletion conditions. The membrane potential was measured using tetra-[ 3 H]phenylphosphonium bromide.](https://figures.cochat.ai/paper-figures/b01e7891765241e4a7d71c59f242a243/diarylquinolines-are-bactericidal-for-dormant-mycobacteria-as-a-result-of-figure-4.png)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“The most promising compounds clinically, the diarylquinolines, have been shown to target the F1Fo-ATP synthase and inhibit ATP synthesis (109, 111, 112).”
From Energetics of Respiration and Oxidative Phosphorylation in Mycobacteria (2014) · cites this paper as [112]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Global Burden of Tuberculosis: Estimated Incidence, Prevalence, and Mortality by Country
Dye, C., Scheele, S., >Dolin, P., Pathania, V., Raviglione, M. C., & for the WHO Global Surveillance and Monitoring Project (1999) · JAMA · doi:10.1001/jama.282.7.677 · Cited by 2,947
The Growing Burden of Tuberculosis: Global Trends and Interactions With the HIV Epidemic
Corbett, E. L., Watt, C. J., Walker, N., Maher, D., Williams, B. G., Raviglione, M. C., & Dye, C. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.9.1009 · Cited by 2,553
A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis
Andries, K., Verhasselt, P., Guillemont, J., Göhlmann, H. W. H., Neefs, J.-M., Winkler, H., Van Gestel, J., Timmerman, P., Zhu, M., Lee, E., et al. (2005) · Science · doi:10.1126/science.1106753 · Cited by 2,191
Self-citationTranscriptional Adaptation of Mycobacterium tuberculosis within Macrophages
Schnappinger, D., Ehrt, S., Voskuil, M. I., Liu, Y., Mangan, J. A., Monahan, I. M., Dolganov, G., Efron, B., Butcher, P. D., Nathan, C., et al. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20030846 · Cited by 1,420
Wayne, L. G., & Hayes, L. G. (1996) · Infection and Immunity · doi:10.1128/iai.64.6.2062-2069.1996 · Cited by 1,141
A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis
Stover, C. K., Warrener, P., VanDevanter, D. R., Sherman, D. R., Arain, T. M., Langhorne, M. H., Anderson, S. W., Towell, J. A., Yuan, Y., McMurray, D. N., et al. (2000) · Nature · doi:10.1038/35016103 · Cited by 1,034
Inhibition of Respiration by Nitric Oxide Induces a Mycobacterium tuberculosis Dormancy Program
Voskuil, M. I., Schnappinger, D., Visconti, K. C., Harrell, M. I., Dolganov, G. M., Sherman, D. R., & Schoolnik, G. K. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20030205 · Cited by 966
Muñoz-Elías, E. J., & McKinney, J. D. (2005) · Nature Medicine · doi:10.1038/nm1252 · Cited by 756
Diarylquinolines target subunit c of mycobacterial ATP synthase
Koul, A., Dendouga, N., Vergauwen, K., Molenberghs, B., Vranckx, L., Willebrords, R., Ristic, Z., Lill, H., Dorange, I., Guillemont, J., et al. (2007) · Nature Chemical Biology · doi:10.1038/nchembio884 · Cited by 547
Self-citationM. tuberculosis persistence, latency, and drug tolerance
Gomez, J. E., & McKinney, J. D. (2004) · Tuberculosis · doi:10.1016/j.tube.2003.08.003 · Cited by 533
Cited by
Items 301–400 of 409
Bambeke, F. V., Glupczynski, Y., Mingeot‐Leclercq, M., & Tulkens, P. M. (2010) · Elsevier eBooks · doi:10.1016/b978-0-323-04579-7.00130-1 · Cited by 3
Naidoo, T. J., Ashokcoomar, S., Truebody, B. E., Mackenzie, J. S., Steyn, A. J. C., & Pillay, M. (2025) · Metabolomics · doi:10.1007/s11306-025-02320-5 · Cited by 2
“Numerous studies demonstrated that the diarylquinolone, BDQ, inhibits the production of ATP through OXPHOS (Andries et al., 2005; Koul et al., 2008; Lamprecht et al., 2016; Mackenzie et al., 2020; Watanabe et al., 2011).”
InfluentialMaleki, M. R. (2026) · Infection and Drug Resistance · doi:10.2147/idr.s568121 · Cited by 2
“Inhibition of ATP biosynthesis leads to bacterial death in both active and inactive states.”
The role of cytochrome oxidases in bacterial virulence
McKay, L. S., Camilli, A., & Cotter, P. A. (2026) · Infection and Immunity · doi:10.1128/iai.00609-24 · Cited by 2
“Excitingly, this drug can target and kill persister cells (17, 101–103) and can be used in combination with existing first-line antimicrobials used to treat tuberculosis (90).”
Dual inhibition of respiratory complexes in Mycobacterium tuberculosis results in bacterial killing
Chapman, C. L., Cook, G. M., & McNeil, M. B. (2026) · Microbiology Spectrum · doi:10.1128/spectrum.00643-26 · Cited by 2
Selectivity of Bedaquiline reacting with different polypeptide chains. Theoretical approach
Bosquez, M., Fomina, L., & Salcedo, R. (2020) · Molecular Simulation · doi:10.1080/08927022.2020.1714042 · Cited by 2
“Theoretically, the binding and blocking of the subunit c rotation, results in the inhibition of ATP production, causing cell death [6,7] (Figure 2).”
BackgroundBrammacharry, U. (2023) · Indian Journal of Pure & Applied Biosciences · doi:10.18782/2582-2845.8983 · Cited by 2
Santosh, M. K. P. (2023) · International Journal of Science and Research (IJSR) · doi:10.21275/sr23802200839 · Cited by 2
Mycobacterial F-ATP Synthase: From Structures to Target Sites to Inhibitors
Harikishore, A., Wong, C. F., Ragunathan, P., Shin, J. S., Dick, T., & Grüber, G. (2024) · Springer eBooks · doi:10.1007/978-981-97-1777-4_5 · Cited by 2
Bundutidi, G. M., Mochizuki, K., Matsuo, Y., Hayashishita, M., Sakura, T., Ando, Y., Cook, G. M., Acharjee, R., Bringaud, F., Boshart, M., et al. (2025) · Communications Biology · doi:10.1038/s42003-025-07611-0 · Cited by 2
“The utility of targeting the OXPHOS pathway is demonstrated by the activity of compound classes that include diarylquinoline and benzothiazinone anti-microbials, exposure to which induces a swift decrease in bacterial viability 8,9 .”
Drug Susceptibility of Individual Mycobacterial Cells
Boot, M., & Rego, E. H. (2019) · Springer eBooks · doi:10.1007/978-3-030-25241-0_11 · Cited by 2
Challenges and Advances in TB Drug Discovery
Khare, G., Nangpal, P., & Tyagi, A. K. (2019) · Springer eBooks · doi:10.1007/978-981-32-9413-4_25 · Cited by 2
Repurposing chlorpromazine and its metabolites for antituberculosis drug discovery
Kigondu, E. M. (2015) · Open University of Cape Town (University of Cape Town) · Cited by 2
Sundararaman, L. (2016) · DR-NTU (Nanyang Technological University) · doi:10.32657/10356/67325 · Cited by 2
Li, X. (2011) · SUNY Digital Repository Support (State University of New York System) · Cited by 2
Tuberculosis: new era for diagnosis and surveillance using whole-genome sequencing-based approaches
Macedo, A. R. F. (2019) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · Cited by 2
Swami, S. (2015) · Research Explorer (The University of Manchester) · Cited by 2
ParA: A Novel Target for Anti-Tubercular Drug Discovery
Nisa, S. (2010) · Open Access Victoria University of Wellington | Te Herenga Waka (Figshare) · doi:10.26686/wgtn.16971664 · Cited by 2
Structural basis for EtfD-mediated coupling of β-oxidation and the respiratory chain in mycobacteria
Courbon, G. M., Makarov, V., Cole, S. T., Schnapinger, D., Ehrt, S., & Rubinstein, J. L. (2026) · The EMBO Journal · doi:10.1038/s44318-026-00726-y · Cited by 1
“…of the adenosine triphosphate (ATP) synthase inhibitor bedaquiline, which kills both replicating and non-replicating M. tuberculosis in vitro (Koul et al, 2008), has validated mycobacterial energy metabolism as a target for the development of new drugs with the potential to shorten TB…”
Bedaquiline: A Promising new agent for the treatment of MDR-TB
Benni, J. M. (2013) · International Journal of Drug Development and Research · Cited by 1
Tan, C., wang, Y., dong, Q., Li, Y., Lu, H., feng, J., Ren, X., Lu, H., Li, P. Z., Wang, R., et al. (2026) · Communications Biology · doi:10.1038/s42003-026-09654-3 · Cited by 1
“Previously,ithasbeenreportedthat non-replicatingmycobacteriawereviablewithonlyatenthofATPlevels comparedtoreplicatingbacilli,butfurtherATPexhaustionwillresultin ef fi cient killing 34 .”
Anand, P., & Akhter, Y. (2026) · Journal of Cellular Biochemistry · doi:10.1002/jcb.70095 · Cited by 1
Niu, J., Zhang, P., Wei, Z., Zou, Y., & Wang, Z. (2026) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2026.1896879 · Cited by 1
“Bedaquiline targets mycobacterial ATP synthase and disrupts ATP homeostasis, providing a rationale for activity against metabolically constrained or dormant mycobacteria in addition to actively replicating bacilli (Koul et al., 2008; Kiel et al., 2015).”
Les nouveaux antituberculeux (2) : nouvelles molécules
Véziris, N. (2013) · Journal des Anti-infectieux · doi:10.1016/j.antinf.2013.06.001 · Cited by 1
The challenge of new drug discovery for
Arnoult, É., Lounis, N., Guillemont, J., & Andries, K. (2011) · Cited by 1
Self-citationBedaquiline: A Novel Addition to Anti-Tubercular Armamentarium
Nandha, R. (2013) · Journal of Biomedical and Pharmaceutical Research · Cited by 1
Tuberculosis: Still a Way to go ahead for a Lead- A Review
Bose, P., Harit, A. K., & Halder, K. K. (2017) · Journal of Analytical & Pharmaceutical Research · doi:10.15406/japlr.2017.05.00161 · Cited by 1
Kishk, S. M., Helal, M. A., Gomaa, M. S., Salama, I., Moustafa, S. M., & Simons, C. (2018) · Records of Pharmaceutical and Biomedical Sciences/Records of Pharmaceutical & Biomedical Sciences · doi:10.21608/rpbs.2018.3874.1004 · Cited by 1
“…ATP synthase enzyme, thus reducing adenosine triphosphate (ATP) levels, and shows some effects on other bacteria but is not effective on the homologous ATPase enzyme in eukaryotes (Andries et al., 2005; Haagsma et al., 2009; De Jonge et al., 2007; Koul et al., 2008; Field et al., 2012).”
BackgroundJeon, A. B., Basaraba, R. J., Borlee, B., Gustafson, D., Jackson, M., Melander, C., & Obregón-Henao, A. (2017) · Digital Collections of Colorado (Colorado State University) · doi:10.25675/3.020311 · Cited by 1
Guillemont, J., Lounis, N., & Andries, K. (2016) · doi:10.4155/fseb2013.14.212 · Cited by 1
Self-citationThe Spectrum of Drug Susceptibility in Mycobacteria
Aldridge, B. B., Keren, I., & Fortune, S. M. (2015) · ASM Press eBooks · doi:10.1128/9781555818845.ch34 · Cited by 1
Respiratory ATP synthesis as drug target for combating tuberculosis
Haagsma, A. C. (2012) · Digital Academic REpository of VU University Amsterdam (Vrije Universiteit Amsterdam) · Cited by 1
de Vos, M. (2013) · SUNScholar (Stellenbosch University) · Cited by 1
Mowa, M. B. (2009) · University of the Witwatersrand, Johannesburg Institutional Repository on DSpace (University of the Witwatersrand, Johannesburg) · Cited by 1
Drug-resistant tuberculosis in France : epidemiology and management
Guglielmetti, L. (2018) · theses.fr (ABES) · doi:10.70675/f9031becz441az410fzb9abz22f6748f883a · Cited by 1
“This gene codes for the c subunit of the transmembrane component (called F0) of the ATP synthase.(136) Bedaquiline binds the c subunit at the level of amino acids 28, 59, 61, 63, and 66:(137) Docking studies have shown that bedaquiline has high affinity for the ATP synthase even at low proton motive force and with low…”
Segala, E. (2012) · OpenGrey (Institut de l'Information Scientifique et Technique) · Cited by 1
Mcdowell, J. R. (2021) · Scholars Archive - University at Albany (University at Albany, State University of New York) · doi:10.54014/11hv-av1r · Cited by 1
Klotoe, J. B. M. (2018) · theses.fr (ABES) · doi:10.70675/0b85e2dfz956dz4573z8754z857a06866fd1 · Cited by 1
The Membrane as a Novel Target Site for Antibiotics to Kill Persisting Bacterial Pathogens
Wu, X., & Hurdle, J. G. (2013) · Antibiotics · doi:10.1002/9783527659685.ch8
Hctor, R. (2012) · InTech eBooks · doi:10.5772/30422
“However, the fact that resistant mutants were isolated “in vitro”, having mutations in the atpE gene (encoding a subunit of ATP synthase) dampens to some extent the expectation of having a novel powerful drug (Koul et al., 2008).”
Drug-resistance in M. tuberculosis & the characterisation of a new anti-tuberculosis drug-candidate
Huitric, E. (2009) · Figshare
Raccourcissement de la durée de traitement de la tuberculose
Dû, D. L. (2015) · Journal des Anti-infectieux · doi:10.1016/j.antinf.2015.07.003
Seelert, H. (2011) · Technischen Universität Darmstadt · doi:10.26083/tuprints-00002646
Baranova, E. A., Montgomery, M. G., Leslie, A. G. W., & Walker, J. E. (2010) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2010.04.100
Nouvelles cibles bactériennes pour les mycobactéries
Sougakoff, W. (2009) · Antibiotiques · doi:10.1016/j.antib.2009.01.003
Andrianaivomananjaona, T., & Haraux, F. (2010) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2010.04.098
Studies on Mycobacterial Response to Low Iron and Oxidative Stress by Proteomics
Rao, P. (2012) · Figshare
Genetic Essentiality, Biochemical and Structural Properties of Fructose 1,6-bisphosphatases II
Gutka, H. J. (2013) · Figshare
Joseph, L. (2015) · ResearchSpace (University of KwaZulu-Natal)
Current Approaches to Tuberculosis Drug Discovery and Development
Mitton‐Fry, M. J., & Hanna, D. L. (2011) · Royal Society of Chemistry eBooks · doi:10.1039/9781849733496-00228
Mechanisms of Action of Antibacterial Agents
Buensalido, J. A. L., DeMarco, C. E., & Lerner, S. (2015) · CRC Press eBooks · doi:10.1201/b17871-13
Thomas, S. T. (2012) · Academic Commons (Stony Brook University)
(2012) · Journal of Functional Ventilation and Pulmonology · doi:10.12699/jfvp.3.8.2012.6
Bedaquiline - A Novel Promising Discovery in Multidrug-Resistant Tuberculosis
Kumar, S., Rani, S., Ch, R., Siwach, E., & Verma, P. (2013)
Regulatory responses to rifampicin exposure in Mycobacterium tuberculosis
Black, P. A. (2015) · SUNScholar (Stellenbosch University)
Menéndez, R. F. (2016) · Library Open Repository (Universidad Complutense Madrid)
Efflux-Mediated Multidrug Tolerance in Replicating Mycobacteria
Adams, K. N. (2012) · ResearchWorks at the University of Washington (University of Washington)
A microfluidics system for drug susceptibility testing in mycobacterium smegmatis.
Luthuli, B. B. (2015) · ResearchSpace (University of KwaZulu-Natal)
Ngcobo, Z. B. (2015) · ResearchSpace (University of KwaZulu-Natal)
Subtil, F. T. (2017) · Americanae (AECID Library)
Kumar, A. (2017) · DR-NTU (Nanyang Technological University) · doi:10.32657/10356/72805
Experimental Characterization of the Mycobacterium tuberculosis Gene Regulatory Network
Minch, K. J. (2012) · ResearchWorks at the University of Washington (University of Washington)
TBHEB 2014-4 Vol 71 Full Printed Journal
DUMAN, M. (2014) · Turkish Bulletin of Hygiene and Experimental Biology · doi:10.5505/turkhijyen.2014.29053
Design of novel F-ATP synthase inhibitors of mycobacterium tuberculosis
Hotra, A. (2018) · DR-NTU (Nanyang Technological University) · doi:10.32657/10356/75829
“Furthermore, the same method was used as one of the methods to validate ATP synthesis as BDQs mode of action [172].”
MethodReview on Tuberculosis: Trends in the Discovery of New and Efficient Chemotherapeutic Agents
Qwebani‐Ogunleye, T., Ejidike, I. P., & Mtunzi, F. M. (2019) · Springer eBooks · doi:10.1007/978-3-030-20283-5_13
Clp-Mediated Regulation of the Mycobacterial Cell Cycle
Kester, J. C. (2017) · Digital Access to Scholarship at Harvard (DASH) (Harvard University)
To eliminate tuberculosis, we must universally encourage treatment of its latent form – Reply
Schraufnagel, D. E. (2015) · Respirology · doi:10.1111/resp.12669
Li, Z., Zhao, S., Li, X., Wang, C., Yao, L., Jin, R., & Zou, X. (2015) · Chinese Journal of Organic Chemistry · doi:10.6023/cjoc201412011
Ion homeostasis in Mycobacterium smegmatis
Vercoe, M., & Blake, R. I. (2020) · Otago University Research Archive (University of Otago)
Chong, S. S. M. (2020) · DR-NTU (Nanyang Technological University) · doi:10.32657/10356/143914
Khusro, A., Aarti, C., Elghandour, M. M. M. Y., & Salem, A. Z. M. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-819985-5.00005-x
Multiscale Modeling of Tuberculosis Disease and Treatment to Optimize Antibiotic Regimens
Cicchese, J. M. (2020) · Deep Blue (University of Michigan) · doi:10.7302/26
Environmental reservoirs of bovine tuberculosis in the European badger (Meles meles)
Powell, S. M. (2026) · Warwick Research Archive Portal (University of Warwick) · doi:10.82444/warw.33830566
Aldrich, C. C., Wallis, R. S., Remmel, R. P., Hegde, P. V., & Stallings, C. L. (2021) · Wiley eBooks · doi:10.1002/0471266949.bmc298
Faculty Opinions recommendation of Targeting Phenotypically Tolerant Mycobacterium tuberculosis.
Bumann, D. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.727366885.793566044
Miller, C. H. (2013) · Open Access Victoria University of Wellington | Te Herenga Waka (Figshare) · doi:10.26686/wgtn.17004946
Structure and regulation of the mycobacterial F1-ATPase
Wong, C. F. (2022) · DR-NTU (Nanyang Technological University) · doi:10.32657/10356/163190
CHALLENGES IN THE DEVELOPMENT OF DRUGS FOR THE TREATMENT OF TUBERCULOSIS – A REVIEW
N, J. S. V. U. (2023) · Zenodo (CERN European Organization for Nuclear Research) · doi:10.5281/zenodo.7561895
Srivastav, Y., Prajapati, A., & Kumar, M. (2023) · International Journal of Pharmaceutical Sciences Review and Research · doi:10.47583/ijpsrr.2023.v82i02.012
Enhancing tuberculosis treatment with host-targeting strategies
Maure, A. (2021) · theses.fr (ABES) · doi:10.70675/95d81016zc31fz4bd0zab28z82b1d06ddc70
Ray, L. F. L. (2021) · theses.fr (ABES) · doi:10.70675/71d68700z0ba8z4252z9a52z7f5bb2bb44ab
Mycobacterium Energy Metabolism as a Promising Target for Anti-TB Drugs
Kaur, B., Sharma, S., Chauhan, I., & Gupta, M. (2025) · Current Topics in Chemistry · doi:10.2174/0129504023342762250325065553
Alvin, A. (2016) · UNSWorks (University of New South Wales, Sydney, Australia) · doi:10.26190/unsworks/18860
Li, L. (2017) · eScholarship@McGill (McGill) · doi:10.82308/19305
Improving Tuberculosis Treatment
Pieterman, E. D. (2021) · EUR Research Repository (Erasmus University Rotterdam)
Harrison, S. H. (2024) · White Rose eTheses Online (University of Leeds, The University of Sheffield, University of York)
Menaquinone depletion resensitises bedaquiline-resistant tuberculosisPreprint
Wetzel, J., Dallow, J., Davis, E., Pearson, W. H., Daems, S., Govaerts, M., Hereijgers, J., Sprangers, J., Truebody, B. E., Maes, V., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.02.10.702511
“In M. tuberculosis , menaquinone-9 (MK-9) mediates electron transfer along the electron transport chain (ETC) and is essential for oxidative phosphorylation during both active and latent infection ( 16-18 ).”
Self-citationIssahaku, A. R., Noreljaleel, A. E. M., Murray, Z., Schutte‐Smith, M., & Wilhelm, A. (2026) · Journal of Pharmaceutical Innovation · doi:10.1007/s12247-026-10488-z
Innovative platforms for drug discovery against mycobacteria: The success and challenges
Nitschke, J., Soldati, T., & Hanna, N. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-36518-8.00021-7
Khouri, I. M. (2012) · theses.fr (ABES) · doi:10.70675/c67f5574z23f9z4b36z92ddz58a2e6e74d16
Implication des enzymes lipolytiques dans la virulence et la survie mycobactérienne
Santucci, P. (2018) · theses.fr (ABES) · doi:10.70675/b1318398z3b3ez47caza99cz49045a043924
Lee, K. Y., Hyun, M., Lee, J. Y., & Kim, H. A. (2026) · Antibiotics · doi:10.3390/antibiotics15050493
“Notably, bedaquiline demonstrates bactericidal activity against both actively replicating and non-replicating mycobacterial populations, including metabolically dormant bacilli that could cause treatment relapse [28,29].”
Repositioning FDA-approved drugs to identify potential mycobacterial FadD23 inhibitors.
Pillay, C. D. (2025) · ResearchSpace (University of KwaZulu-Natal)
Détermination de la cible moléculaire et du mode d'action de la tomatidine et dérivés
Boulet, M. L. (2017) · Knowledge UdeS (Institutional Deposit of the University of Sherbrooke)
Sookkree, S., Sangboonruang, S., Phunpae, P., Thaisakun, S., Phaonakrop, N., Roytrakul, S., & Tragoolpua, K. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27167223
“These agents exhibit potent antibacterial activity against both actively replicating and dormant bacilli due to their superior macrophage penetration [7].”
Al-Nasralla, A. S. H. (2026) · Academic International Journal of Pure Science · doi:10.59675/p421
“…therapeutics: Koul and colleagues showed the bactericidal properties of diarylquinolines towards dormant mycobacteria by interfering with ATP balance [17], while follow-up studies highlighted the role of respiratory flexibility in sustaining Mtb’s viability under varying energy states [18].”
Roy, A., Sau, S., Agnivesh, P. K., Parida, K. K., & Kalia, N. P. (2026) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2026.119984
Metadata
- Authors
- Koul, A., Vranckx, L., Dendouga, N., Balemans, W., Van den Wyngaert, I., Vergauwen, K., Göhlmann, H. W. H., Willebrords, R., Poncelet, A., Guillemont, J., Bald, D., & Andries, K.
- Affiliations
- Johnson & Johnson (France) (FR)
- Vrije Universiteit Amsterdam (NL)
- Corresponding author
- Koul, Anil
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2008-09
- Volume
- 283
- Issue
- 37
- Pages
- 25273-25280
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2164282552
- Cited by
- 364
- References
- 31
- Citations by year
- 2026: 16 · 2025: 17 · 2024: 10 · 2023: 19 · 2022: 16 · 2021: 22 · 2020: 23 · 2019: 25 · 2018: 17 · 2017: 25 · 2016: 15 · 2015: 20 · 2014: 29 · 2013: 20 · 2012: 22
- FWCI
- 14.78
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 4495 d)
- Locations
- Journal of Biological Chemistry (publishedVersion, cc-by)
- PubMed (publishedVersion)
- VU Research Portal (publishedVersion, other-oa)
- Digital Academic REpository of VU University Amsterdam (Vrije Universiteit Amsterdam) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Tuberculosis Research and Epidemiology
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › ATP Synthase and ATPases Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Bacterial Genetics and Biotechnology
- Keywords
- diarylquinolines, bedaquiline, Mycobacterium tuberculosis, dormant mycobacteria, latent tuberculosis infection, ATP synthase inhibition, ATP homeostasis, bactericidal activity, tuberculosis drug targets
- MeSH terms
- Adenosine Triphosphate, Antitubercular Agents, Homeostasis, Models, Biological, Mycobacterium, Mycobacterium bovis, Mycobacterium tuberculosis, Nitric Oxide, Oxygen, Quinolines, RNA, Messenger, Time Factors, Gene Expression Regulation, Bacterial, Mycobacterium smegmatis, Mitochondrial Proton-Translocating ATPases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.